Trevi Therapeutics has completed the pre-specified sample size re-estimation analysis for the ongoing PRISM Phase 2b/3 trial of Haduvio for severe pruritus in patients with prurigo nodularis.
“Severe pruritus in prurigo nodularis is a very serious and difficult-to-treat condition. We are pleased with the re-estimation results midway through the trial which inform the sample size and further reinforces our view that Haduvio may be an effective treatment option for patients with PN,” said Jennifer L. Good, President and CEO of Trevi Therapeutics.